文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

弥漫性肺泡损伤时序分期与急性呼吸窘迫综合征临床结局的关系

The relationship between the chronological phases of diffuse alveolar damage and clinical outcomes in acute respiratory distress syndrome.
PubMed 文献 · J Intensive Care · 2026-07-10
一句话结论肺活检证实的弥漫性肺泡损伤快速进展(7天内增殖期或21天内纤维化期)与ARDS患者28天及60天死亡率显著升高独立相关。

本研究为回顾性研究,纳入2002年1月至2025年12月开胸肺活检或2017年1月至2025年12月经支气管冷冻肺活检确诊的ARDS患者90例,评估组织学证实的弥漫性肺泡损伤时序分期与临床结局的关系。增殖期与纤维化期患者28天死亡率(36.5% vs 43.5%,p=0.556)和60天死亡率(63.5% vs 69.9%,p=0.601)无显著差异。快速进展(7天内出现增殖期或21天内出现纤维化期)患者28天死亡率(47.9% vs 23.8%,p=0.018)和60天死亡率(72.9% vs 50.0%,p=0.025)显著高于无快速进展者。多变量分析显示快速进展为60天死亡率的独立预测因素(HR 2.274,p=0.014)。快速进展者肺活检前PaCO2显著更低(43.4±11.2 vs 51.2±21.1 mmHg,p=0.013)。气胸为最常见的活检相关并发症,发生率17.8%。

要点

  • 快速进展定义为自ARDS诊断至肺活检7天内出现增殖期或21天内出现纤维化期,该组28天死亡率47.9% vs 无快速进展组23.8%(p=0.018),60天死亡率72.9% vs 50.0%(p=0.025)。
  • 多变量分析显示快速进展是60天死亡率的独立预测因素(HR 2.274,p=0.014)。
  • 增殖期与纤维化期患者28天死亡率(36.5% vs 43.5%,p=0.556)和60天死亡率(63.5% vs 69.9%,p=0.601)无显著差异。
  • 快速进展者肺活检前PaCO2显著低于无快速进展者(43.4±11.2 vs 51.2±21.1 mmHg,p=0.013)。
  • 肺活检相关最常见并发症为气胸,发生于17.8%的患者。

适用人群与场景

  • 诊断为ARDS并接受开胸肺活检(2002年1月至2025年12月)或经支气管冷冻肺活检(2017年1月至2025年12月)的患者。

诊断标准与关键阈值

  • 快速进展:自ARDS诊断至肺活检7天内出现增殖期或21天内出现纤维化期。

研究设计与关键结果

  • 回顾性研究纳入90例ARDS患者,比较增殖期与纤维化期以及快速进展与无快速进展的临床结局。
  • 增殖期与纤维化期患者28天死亡率36.5% vs 43.5%(p=0.556),60天死亡率63.5% vs 69.9%(p=0.601),均无显著差异。
  • 快速进展患者28天死亡率47.9% vs 无快速进展23.8%(p=0.018),60天死亡率72.9% vs 50.0%(p=0.025),快速进展组显著更高。
  • 多变量分析显示快速进展为60天死亡率的独立预测因素(HR 2.274,p=0.014)。
  • 快速进展患者肺活检前PaCO2为43.4±11.2 mmHg vs 无快速进展51.2±21.1 mmHg(p=0.013),快速进展组显著更低。
  • 气胸为最常见的活检相关并发症,发生在17.8%的患者中。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。
  • 作者结论:需要更大规模的对照研究和进一步的生理学研究来验证这些发现。

对床旁实践的改变

  • 对于ARDS患者,若肺活检组织学显示快速进展(7天内增殖期或21天内纤维化期),提示28天和60天死亡风险显著升高,多变量分析显示快速进展为60天死亡率的独立预测因素(HR 2.274)。
  • 快速进展患者肺活检前PaCO2显著更低(43.4±11.2 vs 51.2±21.1 mmHg),作者认为需要更大规模对照研究和进一步生理学研究验证这些发现。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Diffuse alveolar damage (DAD) represents the hallmark histopathological feature of acute respiratory distress syndrome (ARDS); however, its prognostic significance remains unclear. This study aimed to evaluate the associations between the chronological phases of histologically confirmed DAD and clinical outcomes in patients with ARDS.

METHODS: In this retrospective study, we included patients diagnosed with ARDS who underwent open lung biopsy between January 2002 and December 2025 or transbronchial lung cryobiopsy between January 2017 and December 2025. Rapid progression was defined as the presence of the proliferative phase within 7 days or the fibrotic phase within 21 days from ARDS diagnosis to lung biopsy.

RESULTS: A total of 90 patients were included in the analysis. No significant differences were observed in 28-day mortality (36.5% vs. 43.5%, p = 0.556) or 60-day mortality (63.5% vs. 69.9%, p = 0.601) between patients in the proliferative and fibrotic phases. In contrast, patients with rapid progression demonstrated significantly higher 28-day mortality (47.9% vs. 23.8%, p = 0.018) and 60-day mortality (72.9% vs. 50.0%, p = 0.025) than those without rapid progression. Multivariable analysis identified rapid progression as an independent predictor of 60-day mortality (hazard ratio, 2.274; p = 0.014). Furthermore, patients with rapid progression had significantly lower PaCO2 levels prior to lung biopsy (43.4 ± 11.2 vs. 51.2 ± 21.1 mmHg, p = 0.013). Pneumothorax was the most common biopsy-related complication, occurring in 17.8% of patients.

CONCLUSION: Rapid progression of DAD was associated with significantly poorer clinical outcomes, and patients with rapid progression had significantly lower PaCO2 before lung biopsy. Larger controlled studies and additional physiological investigations are warranted to validate these findings.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Chang KW, Huang CH, Leu SW, et al. The relationship between the chronological phases of diffuse alveolar damage and clinical outcomes in acute respiratory distress syndrome. J Intensive Care. 2026. PMID: 42432748. doi:10.1186/s40560-026-00911-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。